You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Aggressive B-cell NHL

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma Trial in China (Relmacabtagene

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • +3 more
  • Relmacabtagene Autoleucel
  • +2 more
  • Guangzhou, Guangdong, China
  • +12 more
Oct 24, 2023

Aggressive B-Cell Non-Hodgkin's Lymphoma, Aggressive B-Cell NHL, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial

Not yet recruiting
  • Aggressive B-Cell Non-Hodgkin's Lymphoma
  • +4 more
  • (no location specified)
Dec 16, 2022

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)

Not yet recruiting
  • B-cell Non-Hodgkins Lymphoma (B-NHL)
  • (no location specified)
Jan 5, 2023

NHL, DLBCL, Non-hodgkin's Lymphoma Trial in United Kingdom, United States (AZD9150, Acalabrutinib, AZD6738)

Completed
  • NHL
  • +3 more
  • Los Angeles, California
  • +11 more
Aug 11, 2022

Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma

Completed
Has Results
  • Follicular Lymphoma (FL/Indolent NHL)
  • +4 more
  • Huntsville, Alabama
  • +22 more
Apr 1, 2022

Non Hodgkin's Lymphoma, NHL, Aggressive NHL Trial in United States (Veltuzumab and 90Y-Epratuzumab Tetraxetan, 90Y-epratuzumab

Withdrawn
  • Non Hodgkin's Lymphoma
  • +3 more
  • Veltuzumab and 90Y-Epratuzumab Tetraxetan
  • +2 more
  • Newark, Delaware
  • +6 more
Aug 12, 2021

Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive

Active, not recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • fractionated first dose rituximab
  • Geneva, Switzerland
    University Hospital Geneva
Apr 21, 2023

Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin, Lymphoma, B-Cell Trial in United States (lisocabtagene maraleucel)

Active, not recruiting
  • Lymphoma, Non-Hodgkin
  • +3 more
  • lisocabtagene maraleucel
  • Gilbert, Arizona
  • +40 more
Apr 22, 2022

Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent, Mantle Cell Lymphoma Refractory Trial in Orange,

Recruiting
  • Follicular B-cell Non-Hodgkin's Lymphoma
  • +7 more
  • MB-106
  • Orange, California
  • +3 more
Nov 1, 2022

NHL, NHL, Relapsed, Adult Trial in United States (CLN-978)

Recruiting
  • NHL
  • NHL, Relapsed, Adult
  • Birmingham, Alabama
  • +4 more
May 31, 2023

Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in United States (IMPT-314)

Not yet recruiting
  • Relapsed Non-Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Los Angeles, California
  • +3 more
Apr 12, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • BTK inhibitor
  • PD-1 inhibitor
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023

B-cell NHL, CLL Trial (CARCIK-CD19)

Not yet recruiting
  • B-cell NHL
  • CLL
  • CARCIK-CD19
  • (no location specified)
May 19, 2023

B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma Trial in Saint Louis (Mosunetuzumab)

Recruiting
  • B Cell Lymphoma
  • +5 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 3, 2023

B-Cell Non Hodgkin Lymphoma Trial in Worldwide (Blinatumomab)

Completed
Has Results
  • B-Cell Non Hodgkin Lymphoma
  • Duarte, California
  • +30 more
Dec 18, 2020

Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial in Miami (Mosunetuzumab,

Not yet recruiting
  • Refractory Non-Hodgkin Lymphoma
  • +2 more
  • Miami, Florida
    University of Miami
Aug 3, 2022

Cardiovascular Events Among Adults Relapsed or Refractory

Recruiting
  • Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
  • +9 more
  • Electronic Health Record Review
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Relapsed/Refractory Aggressive B-Cell Malignancies Trial (ONCT-808, Bridging Therapy)

Not yet recruiting
  • Relapsed/Refractory Aggressive B-Cell Malignancies
  • ONCT-808
  • Bridging Therapy
  • (no location specified)
Jan 19, 2023

Relapsed or Refractory Mantle Cell Lymphoma (MCL) Trial in Duarte (BAFFR-CAR T cells)

Recruiting
  • Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
  • BAFFR-CAR T cells
  • Duarte, California
    City of Hope Medical Center
Oct 18, 2022

B-cell Non-Hodgkin Lymphoma (B-NHL) Trial in Austin (UCART20x22, CLLS52)

Recruiting
  • B-cell Non-Hodgkin Lymphoma (B-NHL)
  • UCART20x22
  • CLLS52
  • Austin, Texas
    Sarah Cannon - St. David South Austin Medical Center
Dec 8, 2022

NHL, Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis, Saint Louis (FT596, Rituximab)

Suspended
  • NHL
  • +3 more
  • Minneapolis, Minnesota
  • +1 more
Jan 31, 2023

DLBCL, High Grade B-Cell Lymphoma Trial in United States (Venetoclax, Rituximab, Etoposide)

Completed
  • Diffuse Large B-Cell Lymphoma
  • High Grade B-Cell Lymphoma
  • Boston, Massachusetts
  • +5 more
Aug 23, 2022

Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)

Recruiting
  • Non-hodgkin Lymphoma,B Cell
  • Autologous CD19-STAR-T cell
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2022

DLBCL - Diffuse Large B Cell Lymphoma Trial in Italy

Recruiting
  • DLBCL - Diffuse Large B Cell Lymphoma
    • Bologna, Italy
    • +12 more
    Sep 4, 2023